Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × vistusertib × CNS × Clear all

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3 Breast 3 Other solid neoplasm 2 Genitourinary 2 Gastrointestinal 2 Tumor-Agnostic 1 Lymphoid 1 Gynecologic 1 CNS 1

Conditions

Interventions

Temozolomide 362 Radiotherapy 219 Bevacizumab 162 Magnetic Resonance Spectroscopy 152 Radiosurgery 132 Cyclophosphamide 85 Irinotecan 72 Carboplatin 71 Radiation 68 Etoposide 67 pembrolizumab 66 Nivolumab 53 Surgical Procedures, Operative 48 Specimen Handling 48 Filgrastim 46 Cisplatin 42 Blood Specimen Collection 39 Topotecan 38 Melphalan 37 Vincristine 36 Pemetrexed 34 Radiotherapy, Intensity-Modulated 33 Lomustine 32 Magnetic Resonance Imaging 31 Ipilimumab 31 Surveys and Questionnaires 30 Drug Therapy 30 sargramostim 29 Everolimus 29 Erlotinib Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡